OPKO Health stock rises 13.87 percent to EUR 1.38, volume 16.12 times average

Published on 10/15/2026 at 21:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 revenue rose 4.30 percent to USD 163.58 million. OPKO Health stock costs EUR 1.38 on October 15, 2026, up 13.87 percent versus Nasdaq close.

Intraday move and earnings context

Nasdaq trading lifted OPKO Health stock on October 15, 2026.
Second-quarter 2026 revenue rose 4.30 percent to USD 163.58 million.
OPKO Health stock costs EUR 1.38 at Lang & Schwarz on October 15, 2026 at 9:28 p.m. CEST, up 13.87 percent versus the Nasdaq close.
MarketBeat reported a consensus Hold rating and an average USD 1.55 target on October 15, 2026.

OPK, US68375N1037, Illustration mit AI erstellt.

OPKO Health stock rose 13.87 percent on Nasdaq on October 15, 2026, while the euro quote reached EUR 1.38 in late trading. The move puts trading volume and the upcoming earnings calendar at the center of the market picture.

OPKO Health was trading at EUR 1.38 at Lang & Schwarz on October 15, 2026 at 9:28 p.m. CEST, up 13.87 percent versus the Nasdaq prior close of October 14, 2026.

Volume reaches 16.12 times average

Nasdaq trading showed a price of USD 1.56 at 3:31 p.m. ET, compared with a USD 1.37 prior close. Volume reached 52,253,386 shares against an average of 3,241,096, or 16.12 times the average. The 52-week range ran from USD 0.98 to USD 1.75, leaving the stock 10.86 percent below its high and 59.18 percent above its low.

Second-quarter revenue rose 4.30 percent

The latest reported operating picture remains tied to the second quarter of 2026. Simply Wall St reported revenue of USD 163.58 million, up 4.30 percent from the second quarter of 2025, while the net loss narrowed to USD 8.42 million from USD 148.40 million. Adjusted loss per share was USD 0.01, compared with USD 0.19 a year earlier.

The next major scheduled date is October 28, 2026, when OPKO Health is expected to hold its third-quarter earnings call at 4:30 p.m. ET, according to MarketBeat. Its earnings report is listed for November 4, 2026 after the close, with the date described as an estimate.

Valuation stays below analyst target

MarketBeat reported on October 15, 2026 that six analysts assigned OPKO Health a consensus Hold rating and an average 12-month price target of USD 1.55. The target is 0.64 percent below the Nasdaq quote of USD 1.56, while the finance snapshot showed a market capitalization of USD 1.2 billion and a negative price-to-earnings ratio of 16.30.

Comparison with peers

OPKO Health: plus 13.87 percent, price-to-earnings ratio minus 16.30, market capitalization USD 1.2 billion

Thermo Fisher Scientific (NYSE, USD): plus 3.84 percent, price-to-earnings ratio 37.64, market capitalization USD 258.5 billion

Danaher (NYSE, USD): plus 3.32 percent, price-to-earnings ratio 41.27, market capitalization USD 163.2 billion

Price position after hours

The euro quote was in after-hours trading at Lang & Schwarz, while the Nasdaq session had delivered the underlying daily comparison. OPKO Health operates across diagnostics and pharmaceuticals, with BioReference Laboratories forming the core of its laboratory business.

OPKO Health was trading at EUR 1.38 at Lang & Schwarz on October 15, 2026 at 9:28 p.m. CEST, up 13.87 percent versus the Nasdaq prior close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of OPKO Health stock.